HLX-22 is under clinical development by Shanghai Henlius Biotech and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HLX-22’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HLX-22 overview
HLX-22 (AC-101) is under development for the treatment of solid tumors like breast, gastric cancer, gastroesophageal junction carcinomas and hepatocellular carcinoma. It is a monoclonal antibody. It is administered through intravenous route. The biologic candidate targets human epidermal growth factor receptor 2 (HER2). It is developed based on Yplus technology which enables the production of antibodies with an epitope as its target.
Shanghai Henlius Biotech overview
Shanghai Henlius Biotech (Henlius), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd, is a biopharmaceutical company, which includes research, development, production and marketing of monoclonal antibody products. It develops medicine for oncology, autoimmune and ophthalmic diseases. The company offers products such as rituximab injection for treating chronic lymphocytic leukemia and non-Hodgkin lymphoma; trastuzumab for breast cancer, metastatic gastric cancer and metastatic breast cancer; and adalimumab injection for ankylosing spondylitis, rheumatoid arthritis, plaque psoriasis and uveitis. It also offers bevacizumab injection and serplulimab injection. The company operates research and development centers in Shanghai, China and the US. Henlius is headquartered in Shanghai, China.
For a complete picture of HLX-22’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.